COVID-19 vaccine study letter Mar 2022
Thank you letter from the sponsor for participants enrolled into the Novavax COVID-19 vaccine trial at our Trust
For participants enrolled into the Novavax COVID-19 vaccine trial at our Trust
To: Participants and Site Staff
From: Novavax, 302 Study team
Dear UK Clinical Trial Participants and Site Staff,
We are pleased that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization (CMA) for our COVID-19 vaccine, which will be called Nuvaxovid™ in the UK. This authorization marks the first protein-based vaccine to be approved for use in Great Britain, providing and important additional immunization option.
On behalf of Novavax, I want to express our appreciation to every clinical trial participant and site staff in the United Kingdom for their help, support and contributions to this program. This approval marks a significant milestone in the next phase of tackling the ongoing pandemic. The data from the clinical trial in which you participated played a vital role in this approval and others worldwide, and we are grateful for that.
Novavax study team would like to thank you again for your participation and continued support.
Sincerely,